Sector News

ConvaTec to bolster senior leadership

December 5, 2017
Life sciences

Medical product and technology company ConvaTec Group PLC said on Monday it has made several senior appointments as a result of changes to its organisational structure.

From January 1, 2018 the group’s four franchises will he headed by Franchise Presidents who will report directly to the Chief Executive Officer, and will responsible for the development and delivery of its strategic plans across all its target markets, as well as marketing and research & development within their franchises.

Peter Byloos will be appointed as head of Advanced Wound Care. He will be joining from European investment company Gimv, where he is partner for healthcare for nearly three years since the start of 2015.

Erik Zimmer will continue as vice president & general manager of Ostomy Care, with an appointment of a president for the franchise to be made in due course.

ConvaTec will promote current Interim President of Europe, Middle East & Africa Frank Gehres as president of Continence and Critical Care, with Mads Haugaard reporting to him as vice president & general manager.

Gehres will be replaced as president of Europe, Middle East & Africa by Kjersti Grimsrud, who will be joining from rapid point-of-care diagnostics tests manufacturer Alere Inc, where she was president of Europe & Middle East and president International for three and a half years since 2014.

John Lindskog will continue as president with responsibility over the Infusion Devices franchise.

In addition, ConvaTec will appoint Sean McGrath as executive vice president of global human resources, joining from the World Bank Group where he was vice president of human resources for five years since 2012. He will be replacing Marc Reuss, who has held the role for two years since 2015.

Also, President of Global Franchises and Innovation Symeria Hudson, will be leaving with effect at the end of 2017, after nearly two years in the role since March 2016.

“These important changes to our organisation will drive a greater focus on the leadership of our Franchises and on their performance as business units of ConvaTec, as well as providing better leverage of our strong new product pipeline. I am confident that this new structure will enable us to drive increased value from our leading market positions across each of the businesses,” said Chief Executive Officer Paul Moraviec.

Shares in ConvaTec were up 1.2% at 201.90 pence on Monday.

By Dayo Laniyan

Source: Alliance News

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach